Stockreport

Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates

Sana Biotechnology, Inc.  (SANA) 
PDF Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Enrolling [Read more]